Corvus Pharmaceuticals is a biotechnology business based in the US. Corvus Pharmaceuticals shares (CRVS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.95 – an increase of 6.55% over the previous week. Corvus Pharmaceuticals employs 28 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $8.95 |
|---|---|
| 52-week range | $1.30 - $10.00 |
| 50-day moving average | $7.07 |
| 200-day moving average | $3.53 |
| Wall St. target price | $15.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.99 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.95 from 2024-11-22
| 1 week (2024-11-18) | 7.31% |
|---|---|
| 1 month (2024-10-25) | 7.70% |
| 3 months (2024-08-23) | 108.14% |
| 6 months (2024-05-24) | 334.47% |
| 1 year (2023-11-24) | 513.01% |
|---|---|
| 2 years (2022-11-25) | 900.22% |
| 3 years (2021-11-24) | 164.79% |
| 5 years (2019-11-25) | 184.13% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -23.83% |
| Return on equity TTM | -44.91% |
| Profit margin | 0% |
| Book value | $0.79 |
| Market Capitalization | $574.5 million |
TTM: trailing 12 months
We're not expecting Corvus Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Corvus Pharmaceuticals's shares have ranged in value from as little as $1.3 up to $10. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corvus Pharmaceuticals's is 1.044. This would suggest that Corvus Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Corvus Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.